Covance

Yahoo Profile of CVD:  Covance, Inc., a drug development services company, provides early-stage and late-stage product development services primarily to the pharmaceutical, biotechnology, and medical device industries worldwide.  This stock has been a big winner in the biotech area.  Cramer gave it a buy signal several months ago before the market correction.  Technically the stock may be at a crossroads.  It has challenged the 200 day MA a couple of times now.  The stock I think will remain around current levels until quarterly earnings release on April 28.  I’m not sure if I would take a position prior to earnings but I think the report will give a hint as to whether the stock totally breaks its uptrend or we are just in a correction and the stock moves higher from here.  Here is the chart.